Pneumococcal conjugate vaccines - A European perspective

International Journal of Medical Microbiology

Volumn 294, Issue 5, 2004, Pages 277-294

  Reinert, Ralf René ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

7 valent; Coverage; Europe; Resistance; Streptococcus pneumoniae; Vaccine

Indexed keywords

PNEUMOCOCCUS VACCINE;

ANTIBIOTIC RESISTANCE; BACTERIAL MENINGITIS; BACTERIAL PNEUMONIA; DRUG EFFICACY; DRUG SAFETY; EASTERN EUROPE; EUROPE; FRANCE; GERMANY; HIGH RISK POPULATION; HUMAN; IMMUNOGENICITY; INFECTION CONTROL; LICENSING; NETHERLANDS; OTITIS MEDIA; REVIEW; SEROTYPE; SPAIN; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

EID: 6044254852     PISSN: 14384221     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijmm.2004.04.004     Document Type: Review

References (174)

1. Adam, D., 2002. Global antibiotic resistance in Streptococcus pneumoniae. J. Antimicrob. Chemother. 50 (Suppl. 1), 1-5.
2. Advisory Committee on Immunization Practices (ACIP), 2000. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep., vol. 49, pp. 1-35.
3. Ahman, H., Käyhty, H., Tamminen, P., Vuorela, A., Malinoski, F., Eskola, J., 1996. Pentavalent pneumococcal oligosaccharide conjugate vaccine PncCRM is well-tolerated and able to induce an antibody response in infants. Pediatr. Infect. Dis. J. 15, 134-139.
4. Ahman, H., Käyhty, H., Lehtonen, H., Leroy, O., Froeschle, J., Eskola, J., 1998. Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid conjugate vaccine is immunogenic in early infancy and able to induce immunologic memory. Pediatr. Infect. Dis. J. 17, 211-216.
5. Ahman, H., Käyhty, H., Vuorela, A., Leroy, O., Eskola, J., 1999. Dose dependency of antibody response in infants and children to pneumococcal polysaccharides conjugated to tetanus toxoid. Vaccine 17, 2726-2732.
6. Ahmed, F., Steinhoff, M.C., Rodriguez-Barradas, M.C., Hamilton, R.G., Musher, D.M., Nelson, K.E., 1996. Effect of human immunodeficiency virus type 1 infection on the antibody response to a glycoprotein conjugate pneumococcal vaccine: results from a randomized trial. J. Infect. Dis: 173, 83-90.
7. American Academy of Pediatrics Committee on Infectious Diseases, 2000. American Academy of Pediatrics. Committee on Infectious Diseases. Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics 106, 362-366.
8. Anderson, E.L., Kennedy, D.J., Geldmacher, K.M., Donnelly, J., Mendelman, P.M., 1996. Immunogenicity of heptavalent pneumococcal conjugate vaccine in infants. J. Pediatr. 128, 649-653.
9. Anttila, M., Voutilainen, M., Jantti, V., Eskola, J., Käyhty, H., 1999. Contribution of serotype-specific IgG concentration, IgG subclasses and relative antibody avidity to opsonophagocytic activity against Streptococcus pneumoniae. Clin. Exp. Immunol. 118, 402-407.
10. Appelbaum, P.C., 2002. Resistance among Streptococcus pneumoniae: implications for drug selection. Clin. Infect. Dis. 34, 1613-1620.
11. Arguedas, A., Loaiza, C., Ferez, A., 2001. A randomized, placebo-controlled, dose-range study to evaluate the immunogenicity of a tetravalent pneumococcal protein D conjugate vaccine in infants, and boostability by plain polysaccharide. In: Abstracts of the 19th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID), Istanbul, Turkey, March 26-28, 2001.
12. Asensi, F., De Jose, M., Lorente, M., Moraga, F., Ciuryla, V., Arikian, S., Casciano, R., Vento, M., 2004. A pharmacoeconomic evaluation of seven-valent pneumococcal conjugate vaccine in Spain. Value Health 7, 36-51.
13. Austrian, R., 1981. Pneumococcus: the first one hundred years. Rev. Infect. Dis. 3, 183-189.
14. Austrian, R., Douglas, R.M., Schiffman, G., Coetzee, A.M., Koornhof, H.J., Hayden-Smith, S., Reid, R.D.W., 1976. Prevention of pneumococcal pneumonia by vaccination. Trans. Assoc. Am. Physicans 89, 184-192.
15. Avery, O.T., Goebel, W.E., 1929. Chemo-immunological studies on conjugated carbohydrate-proteins. II immunological specifity of synthetic sugar-protein antigens. J. Exp. Med. 50, 533-550.
16. Baquero, F., 1999. Evolving resistance patterns of Streptococcus pneumoniae: a link with long-acting macrolide consumption?. J. Chemother. 11 (Suppl. 1), 35-43.
17. Barnett, E.D., Pelton, S.I., Cabral, H.J., Eavey, R.D., Allen, C., Cunningham, M.J., McNamara, E.R., Klein, J.I., 1999. Immune response to pneumococcal conjugate and polysaccharide vaccines in otitis-prone and otitis-free children. Clin. Infect. Dis. 29, 191-192.
18. Bennett, D., Lennon, B., Humphreys, H., Cafferkey, M., 2003. Penicillin susceptibility and epidemiological typing of invasive pneumococcal isolates in the Republic of Ireland. J. Clin. Microbiol. 41, 3641-3648.
19. Bernaola Iturbe, E., Aristegui Fernandez, J., Herranz Aguirre, M., Garcia Calvo, C., Fernandez Perez, C., Grupo de Estudio de Enfermedad Invasora Neumococica en el Pais Vasco-Navarra, 2002. Study of the incidence of invasive pneumococcal disease in neonates and children aged less than 5 years in the Basque country and Navarre (Spain). An. Esp. Pediatr. 57, 301-309 (Spanish).
20. Black, S.B., Shinefield, H., Fireman, B., Lewis, E., Ray, P., Hansen, J.R., Elvin, L., Ensor, K.M., Hackell, J., Siber, G., Malinoski, F., Madore, D., Chang, I., Kohberger, R., Watson, W., Austrian, R., Edwards, K., 2000. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr. Infect. Dis. J. 19, 187-195.
21. Black, S.B., Shinefield, H.R., Hansen, J., Elvin, L., Laufer, D., Malinoski, F., 2001. Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J. 20, 1105-1107.
22. Black, S.B., Shinefield, H.R., Ling, S., Hansen, J., Fireman, B., Spring, D., Noyes, J., Lewis, E., Ray, P., Lee, J., Hackell, J., 2002. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr. Infect. Dis. J. 21, 810-815.
23. Black, S.B., Shinefield, H., Elvin, L., Ray, P., Lewis, E., Fireman, B., 2003. Impact of the introduction of pneumococcal conjugate vaccine on the epidemiology of invasive disease in children and adults within Northern California Kaiser Permanente (NCKP), In: Conference Proceedings of the 41st Annual Meeting of the Infectious Disease Society of America, San Diego, CA, 2003, p. 498.
24. Blum, M.D., Dagan, R., Mendelman, P.M., Pinsk, V., Giordani, M., Li, S., Bohidar, N., McNeely, T.B., 2000. A comparison of multiple regimens of pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine and pneumococcal polysaccharide vaccine in toddlers. Vaccine 18, 2359-2367.
25. Bozdogan, B., Appelbaum, P.C., Kelly, L.M., Hoellman, D.B., Tambic-Andrasevic, A., Drukalska, L., Hryniewicz, W., Hupkova, H., Jacobs, M.R., Kolman, J., Konkoly Thege, M., Miciuleviciene, J., Pana, M., Setchanova, L., Trupl, J., Urbaskova, P., 2003. Activity of telithromycin and seven other agents against 1034 pediatric Streptococcus pneumonias isolates from ten central and eastern European centers. Clin. Microbiol. Infect. 9, 653-661.
26. Brenner, H., 1994. Application of capture-recapture methods for disease monitoring: potential effects of imperfect record linkage. Methods Infect. Med. 33, 502-506.
27. Brenner, H., 1996. Effects of misdiagnoses on disease monitoring with capture-recapture methods. J. Clin. Epidemiol. 49, 1303-1307.
28. Briles, D.E., Hollingshead, S.K., Nabors, O.S., Paton, J.C., Brooks-Walter, A., 2000. The potential for using protein vaccines to protect against otitis media caused by Streptococcus pneumoniae. Vaccine 19 (Suppl. 1), S87-95.
29. Capeding, M.Z., Puumalainen, T., Gepanayao, C.P., Käyhty, H., Lucero, M.G., Nohynek, H., 2003. Safety and immunogenicity of three doses of an eleven-valent diphtheria toxoid and tetanus protein-conjugated pneumococcal vaccine in Filipino infants. BMC Infect. Dis. 3, 17.
30. Cars, O., Molstad, S., Melander, A., 2001. Variation in antibiotic use in the European Union. Lancet 357, 1851-1853.
31. Centers for Disease Control and Prevention, 2002. From the Centers for Disease Control and Prevention. Updated recommendations on the use of pneumococcal conjugate vaccine in a setting of vaccine shortage-Advisory Committee on Immunization Practices. JAMA 287, 833-834.
32. Chan, C.Y., Molrine, D.C., George, S., Tarbell, N.J., Mauch, P., Diller, L., Shamberger, R.C., Phillips, N.R., Goorin, A., Ambrosino, D.M., 1996. Pneumococcal conjugate vaccine primes for antibody responses to polysaccharide pneumococcal vaccine after treatment of Hodgkin's disease. J. Infect. Dis. 173, 256-258.
33. Choo, S., Seymour, L., Morris, R., Quataert, S., Lockhart, S., Cartwright, K., Finn, A., 2000. Immunogenicity and reactogenicity of a pneumococcal conjugate vaccine administered combined with a Haemophilus influenzae type B conjugate vaccine in United Kingdom infants. Pediatr. Infect. Dis. J. 19, 854-862.
34. Claes, C., Graf von der Schulenburg, J.M., 2003. Cost effectiveness of pneumococcal vaccination for infants and children with the conjugate vaccine PnC-7 in Germany. Pharmacoeconomics 21, 587-600.
35. Concepcion, N.F., Frasch, C.E., 2001. Pneumococcal type 22F polysaccharide absorption improves the specificity of a pneumococcal- polysaccharide enzyme-linked immunosorbent assay. Clin. Diagn. Lab. Immunol. 8, 266-272.
36. Dagan, R., Melamed, R., Zamir, O., Leroy, O., 1997a. Safety and immunogenicity of tetravalent pneumococcal vaccines containing 6B, 14, 19F and 23F polysaccharides conjugated to either tetanus toxoid or diphtheria toxoid in young infants and their boosterability by native polysaccharide antigens. Pediatr. Infect. Dis. J. 16, 1053-1059.
37. Dagan, R., Muallem, M., Melamed, R., Leroy, O., Yagupsky, P., 1997b. Reduction of pneumococcal nasopharyngeal carriage in early infancy after immunization with tetravalent pneumococcal vaccines conjugated to either tetanus toxoid or diphtheria toxoid. Pediatr. Infect. Dis. J. 16, 1060-1064.
38. Dagan, R., Givon-Lavi, N., Zamir, O., Sikuler-Cohen, M., Guy, L., Janco, J., Yagupsky, P., Fraser, D., 2002. Reduction of nasopharyngeal carriage of Streptococcus pneumonias after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers. J. Infect. Dis. 185, 927-936.
39. Dagan, R., Givon-Lavi, N., Zamir, O., Fraser, D., 2003. Effect of a nonavalent conjugate vaccine on carriage of antibiotic-resistant Streptococcus pneumoniae in day-care centers. Pediatr. Infect. Dis. J. 22, 532-540.
40. Dagan, R., Käyhty, H., Wuorimaa, T., Yaich, M., Bailleux, F., Zamir, O., Eskola, J., 2004. Tolerability and immunogenicity of an eleven valent mixed carrier Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid or tetanus protein conjugate vaccine in Finnish and Israeli infants. Pediatr. Infect. Dis. J. 23, 91-98.
41. Daum, R.S., Hogerman, D., Rennels, M.B., Bewley, K., Malinpski, F., Rothstein, E., Reisinger, K., Block, S., Keyserling, H., Steinhoff, M., 1997. Infant immunization with pneumococcal CRM197 vaccines: effect of saccharide size on immunogenicity and interactions with simultaneously administered vaccines. J. Infect. Dis. 176, 445-455.
42. Decousser, J.W., Ovetchkine, P., Collignon, A., Chaplain, C., Estrangin, E., Fremaux, A., Reinert, P., Foucaud, P., Ghnassia, J.C., Cohen, R., Gaudelus, J., Allouch, P.Y., 2003. Multicentre study of the molecular epidemiology, serotypes and antimicrobial susceptibility patterns of invasive Streptococcus pneumoniae invasive isolated from children in the Ille de France area. Eur. J. Clin. Microbiol. Infect. Dis. 23, 27-33.
43. Dobay, O., Rozgonyi, F., Hajdu, E., Nagy, E., Knausz, M., Amyes, S.G., 2003. Antibiotic susceptibility and serotypes of Streptococcus pneumoniae isolates from Hungary. J. Antimicrob. Chemother. 51, 887-893.
44. Eriksson, M., Henriques, B., Ekdahl, K., 2000. Epidemiology of pneumococcal infections in Swedish children. Acta Paediatr. Suppl. 89, 35-39.
45. Eskola, J., Anttila, M., 1999. Pneumococcal conjugate vaccines. Pediatr. Infect. Dis. J. 18, 543-551.
46. Eskola, J., Takala, A.K., Kela, E., Pekkanen, E., Kalliokoski, R., Leinonen, M., 1992. Epidemiology of invasive pneumococcal infections in children in Finland. JAMA 268, 3323-3327.
47. Eskola, J., Kilpi, T., Palmu, A., Jokinen, J., Haapakoski, J., Herva, E., Takala, A., Käyhty, H., Karma, P., Kohberger, R., Siber, G., Mäkelä, P.H., 2001. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N. Engl. J. Med. 344, 403-409.
48. Ess, S.M., Schaad, U.B., Gervaix, A., Pinosch, S., Szucs, T.D., 2003. Cost-effectiveness of a pneumococcal conjugate immunisation program for infants in Switzerland. Vaccine 21, 3273-3281.
49. Fattom, A., Lue, C., Szu, S.C., Mestecky, J., Schiffman, G., Bryla, D., Vann, W.F., Watson, D., Kimzey, L.M., Robbins, J.B., et al., 1990. Serum antibody response in adult volunteers elicited by injection of Streptococcus pneumonias type 12F polysaccharide alone or conjugated to diphtheria toxoid. Infect. Immun. 58, 2309-2312.
50. Fedson, D.S., Musher, D.M., 2003. Pneumococcal polysaccharide vaccine. In: Plotkin, S.A., Orenstein, W.A. (Eds.), Vaccines, fourth ed. Saunders, Philadelphia (Chapter 22).
51. Felmingham, D., Reinert, R.R., Hirakata, Y., Rodloff, A., 2002. Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and compatative in vitro activity of the ketolide, telithromycin. J. Antimicrob. Chemother. 50 (Suppl. S1), 25-37.
52. Fenoll, A., Jado, I., Vicioso, D., Perez, A., Casal, J., 1998. Evolution of Streptococcus pneumoniae serotypes and antibiotic resistance in Spain: update (1990-1996). J. Clin. Microbiol. 36, 3447-3454.
53. Fireman, B., Black, S.B., Shinefield, H.R., Lee, J., Lewis, E., Ray, P., 2003. Impact of the pneumococcal conjugate vaccine on otitis media. Pediatr. Infect. Dis. J. 22, 10-16.
54. Gatchalian, S., Borja-Tabora, C., Bermal, N., Hohenboken, M., Peeters, P., 2001. A randomized, placebo-controlled study to evaluate the immunogenicity of an 11-valent pneumococcal protein D conjugate vaccine administered as primary vaccination to infants at 6, 10 and 14 weeks of age. In: Abstracts of the 19th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID), Istanbul, Turkey, March 26-28, 2001.
55. George, R.C., 2003. Invasive pneumococcal infection, England and Wales. CDR Weekly 13.
56. Geslin, P., Fremaux, A., Sissia, G., Spicq, C., 1998. Streptococcus pneumoniae: serotypes, invasive and antibiotic resistant strains. Current situation in France. Presse. Med. 27 (Suppl. 1), 21-27.
57. Giebink, G.S., Daly, K.A., Le, C.T., et al., 2002. Pneumococcal (PnC) conjugate vaccine (PCV) as maternal and infant immunogens. In: Abstracts of the 3rd International Symposium on Pneumococci and Pneumococcal Diseases, Anchorage, May 5-8, 2002.
58. Givon-Lavi, N., Fraser, D., Dagan, R., 2003. Vaccination of day-care center attendees reduces carriage of Streptococcus pneumoniae among their younger siblings. Pediatr. Infect. Dis. J. 22, 524-532.
59. Goldblatt, D., Akoto, A.Y., Ashton, L., Asafo-Adjei, E., Brainsby, K., Twumasi, P., Baffoe-Bonnie, B., 2000a. Immunogenicity and the generation of immune memory following 9-valent pneumococcal conjugate vaccination in Ghanaian infants with sickle cell disease. In: Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; Toronto, Canada. American Society for Microbiology, Washington, DC.
60. Goldblatt, D., Akoto, I., Ahton, L., 2000b. Poster no. 42: Does one dose of pneumococcal conjugate vaccine induce immunological memory in toddlers? In: Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; Toronto, Canada. American Society for Microbiology, Washington, DC.
61. Guttormsen, H.K., Sharpe, A.M., Chandraker, A.K., Brigtsen, A.K., Sayegh, M.H., Kasper, D.L., 1999. Cognate stimulatory B-cell-T-cell interactions are critical for T-cell help recruited by glycoconjugate vaccines. Infect. Immun. 67, 6375-6384.
62. Harbarth, S., Albrich, W., Brun-Buisson, C., 2002. Outpatient antibiotic use and prevalence of antibiotic-resistant pneumococci in France and Germany: a sociocultural perspective. Emerg. Infect. Dis. 8, 1460-1467.
63. Hausdorff, W.P., Bryant, J., Kloek, C., Paradiso, P.R., Siber, G.R., 2000a. The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II. Clin. Infect. Dis. 30, 122-140.
64. Hausdorff, W.P., Bryant, J., Paradiso, P.R., Siber, G.R., 2000b. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin. Infect. Dis. 30, 100-121.
65. Hausdorff, W.P., Siber, G., Paradiso, P.R., 2001. Geographical differences in invasive pneumococcal disease rates and serotype frequency in young children. Lancet 357, 950-952.
66. Henriques Normark, B., Kalin, M., Ortqvist, A., Akerlund, T., Liljequist, B.O., Hedlund, J., Svenson, S.B., Zhou, J., Spratt, B.C., Normark, S., Kallenius, G., 2001. Dynamics of penicillin-susceptible clones in invasive pneumococcal disease. J. Infect. Dis. 184, 861-869.
67. Hermans, P.W.M., Sluijter, M., Elzenaar, K., van Veen, A., Schonkeren, J., Nooren, F., van Leeuwen, W., de Neeling, A., van Klingeren, B., Verbrugh, H., de Groot, R., 1997. Penicillin-resistant Streptococcus pneumoniae in the Netherlands: results of a 1-year molecular epidemiologic survey. J. Infect. Dis. 175, 1413-1422.
68. Hollingshead, S.K., Briles, D.E., 2001. Streptococcus pneumoniae: new tools for an old pathogen. Curr. Opin. Microbiol. 4, 71-77.
69. Hryniewicz, W., 2003. Alexander Project - 5 years in Poland. Pol. Merkuriusz. Lek. 14, 5-8.
70. Johnson, S.E., Rubin, L., Romero-Steiner, S., Dykes, J.K., Pais, L.B., Rizvi, A., Ades, E., Carlone, G.M., 1999. Correlation of opsonophagocytosis and passive protection assays using human anticapsular antibodies in an infant mouse model of bacteremia for Streptococcus pneumoniae. J. Infect. Dis. 180, 133-140.
71. Jokinen, J., Ahmann, H., Kilpi, T., et al., 2002. The concentration of antipneumococcal antibodies as a serological correlate of protection - a case study of acute otitis media. In: Abstracts of the 3rd International Symposium on Pneumococci and Pneumococcal Diseases, Anchorage, May 5-8, 2002.
72. Jones, M.E., Blosser-Middleton, R.S., Critchley, I.A., Karlowsky, J.A., Thornsberry, C., Sahm, D.F., 2003. In vitro susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: a European multicenter study during 2000-2001. Clin. Microbiol. Infect. 9, 590-599.
73. Jonsdottir, I., Sigurdardottir, S., Gudnason, I., et al., 2000. Concomitant administration of octavalent pneumococcal polysaccharide conjugate vaccine, Pnc-D, and Haemophilus influenzae conjugate vaccine, PRP-D, sharing the carrier DT, may induce interference in infants. In: Abstracts of the 2nd International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD), Sun City, South Africa, 2000. Abstract P 39.
74. Kaltoft, M., Zeuthen, N., Konradsen, H.B., 2000. Epidemiology of invasive pneumococcal infections in children aged 0-6 years in Denmark: a 19-year nationwide surveillance study. Acta Paediatr. 89 (Suppl.), 3-10.
75. Käyhty, H., Ahman, H., Ronnberg, P.R., Tillikainen, R., Eskola, J., 1995. Pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine is immunogenic in infants and children. J. Infect. Dis. 172, 1273-1278.
76. Kilpi, T., Ahman, H., Jokinen, J., Lankinen, K.S., Palmu, A., Savolainen, H., Gronholm, M., Leinonen, M., Hovi, T., Eskola, J., Käyhty, H., Bohidar, N., Sadoff, J.C., Mäkelä, P.H., 2003. Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 1666 children. Clin. Infect. Dis. 37, 1155-1164.
77. King Jr., J.C., Vink, P.E., Parley, J.J., Parks, M., Smilie, M., Madore, D., Lichenstein, R., Malinoski, F., 1996. Comparison of the safety and immunogenicity of a pneumococcal conjugate with a licensed polysaccharide vaccine in human immunodeficiency virus and non-human immunodeficiency virus-infected children. Pediatr. Infect. Dis. J. 15, 192-196.
78. Klugman, K.P., 2001. Antibiotic selection of multiply resistant pneumococci. Clin. Infect. Dis. 33, 489-491.
79. Klugman, K.P., 2003. The role of clonality in the global spread of fluoroquinolone-resistant bacteria. Clin. Infect. Dis. 36, 783-785.
80. Klugman, K.P., Madhi, S.A., Huebner, R.E., Kohberger, R., Mbelle, N., Pierce, N., 2003. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N. Engl. J. Med. 349, 1341-1348.
81. Krause, V.L., Reid, S.J., Merianos, A., 2000. Invasive pneumococcal disease in the Northern Territory of Australia, 1994-1998. Med. J. Aust. 173 (Suppl.), S27-S31.
82. Kroon, P.P., van Dissel, J.T., Ravensbergen, E., Nibbering, P.M., van Furth, R., 2000. Enhanced antibody response to pneumococcal polysaccharide vaccine after prior immunization with conjugate pneumococcal vaccine in HIV-infected adults. Vaccine 19, 886-894.
83. Kyaw, M.H., Christie, P., Jones, LG., Campbell, H., 2002a. The changing epidemiology of bacterial meningitis and invasive non-meningitic bacterial disease in Scotland during the period 1983-99. Scand. J. Infect. Dis. 34, 289-298.
84. Kyaw, M.H., Clarke, S., Jones, I.G., Campbell, H., 2002b. Incidence of invasive pneumococcal disease in Scotland, 1988-99. Epidemiol. Infect. 128, 139-147.
85. Kyaw, M.H., Christie, P., Clarke, S.C., Mooney, J.D., Ahmed, S., Jones, I.G., Campbell, H., 2003. Invasive pneumococcal disease in Scotland, 1999-2001: Use of record linkage to explore associations between patients and disease in relation to future vaccination policy. Clin. Infect. Dis. 37, 1283-1291.
86. Lafong, A.C., Crothers, E., Bamford, K.B., Rooney, P.J., 1988. Distribution of serotypes and antibiotic resistance among pneumococci in Northern Ireland. J. Infect. 16, 235-242.
87. Laurichesse, H., Grimaud, O., Waight, P., Johnson, A.P., George, R.C., Miller, E., 1998. Pneumococcal bacteraemia and meningitis in England and Wales, 1993-1995. Commun. Dis. Public Health 1, 22-27.
88. Le, C., 2000. Cost-effectiveness of pneumococcal vaccine. JAMA 284, 440-441.
89. Lee, L.H., Frasch, C.E., Falk, L.A., Klein, D.L., Deal, C.D., 2003. Correlates of immunity for pneumococcal conjugate vaccines. Vaccine 21, 2199-2205.
90. Lesinski, G.B., Smithson, S.L., Srivastava, N., Chen, D., Widera, G., Westerink, M.A., 2001. A DNA vaccine encoding a peptide mimic of Streptococcus pneumoniae serotype 4 capsular polysaccharide induces specific anti-carbohydrate antibodies in Balb/c mice. Vaccine 19, 1717-1726.
91. Lieu, T., Ray, G.T., Black, S., Shinefield, H., Butler, J., Miller, M., 2000a. Cost-effectiveness of pneumococcal vaccine. JAMA 284, 440-441.
92. Lieu, T.A., Ray, G.T., Black, S.B., Butler, J.C., Klein, J.O., Breiman, R.F., Miller, M.A., Shinefield, H.R., 2000b. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. JAMA 283, 1460-1468.
93. Lipsitch, M., 1999. Bacterial vaccines and serotype replacement: lessons from Haemophilus influenzae and prospects for Streptococcus pneumoniae. Emerg. Infect. Dis. 5, 336-345.
94. Lipsitch, M., 2001. Interpreting results from trials of pneumococcal conjugate vaccines: a statistical test for detecting vaccine-induced increases in carriage of nonvacine serotypes. Am. J. Epidemiol. 154, 85-92.
95. Lipsitch, M., Dykes, J.K., Johnson, S.E., Ades, E.W., King J., Briles, D.E., Carlone, G.M., 2000. Competition among Streptococcus pneumoniae for intranasal colonization in a mouse model. Vaccine 18, 2895-2901.
96. Lue, C., Prince, S.J., Fattom, A., Schneerson, R., Robbins, J.B., Mestecky, J., 1990. Antibody-secreting peripheral blood lymphocytes induced by immunization with a conjugate consisting 02,of Streptococcus pneumoniae type 12F polysaccharide and diphtheria toxoid. Infect. Immun. 58, 2547-2554.
97. Mao, C., Harper, M., McIntosh, K., Reddington, C., Cohen, J., Bachur, R., Caldwell, B., Hsu, H.W., 1996. Invasive pneumococcal infections in human immunodeficiency virus-infected children. J. Infect. Dis. 173, 870-876.
98. Marton, A., 1992. Pneumococcal antimicrobial resistance: the problem in Hungary. Clin. Infect. Dis. 15, 106-111.
99. Marion, A., Gulyas, M., Munoz, R., Tomasz, A., 1991. Extremely high incidence of antibiotic resistance in clinical isolates of Streptococcus pneumoniae in Hungary. J. Infect. Dis. 163, 542-548.
100. Mbelle, N., Huebner, R.E., Wasas, A.D., Kimura, A., Chang, I., Klugman, K.P., 1999. Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. J. Infect. Dis. 180, 1171-1176.
101. Miernyk, K.M., Parkinson, A.J., Rudolph, K.M., Petersen, K.M., Bulkow, L.R., Greenberg, O.P., Ward, J.I., Brenneman, G., Reid, R., Santosham, M., 2000. Immunogenicity of a heptavalent pneumococcal conjugate vaccine in Apache and Navajo Indian, Alaska Native, and Non-Native American children aged <2 years. Clin. Infect. Dis. 31, 34-41.
102. Miller, E., Waight, P., Efstratiou, A., Brisson, M., Johnson, A., George, R., 2000. Epidemiology of invasive and other pneumococcal disease in children in England and Wales 1996-1998. Acta Paediatr. 89, 11-16.
103. Molrine, D.C., George, S., Tarbell, N., Mauch, P., Diller, L., Neuberg, D., Shamberger, R.C., Anderson, E.L., Phillips, N.R., Kinsella, K., et al., 1995. Antibody responses to polysaccharide and polysaccharide-conjugate vaccines after treatment of Hodgkin disease. Ann. Int. Med. 123, 828-834.
104. Mufson, M.A., Krause, H.E., Schiffman, G., 1984. Reactivity and antibody responses of volunteers given two or three doses of pneumococcal vaccine. Proc. Soc. Exp. Biol. Med. 177, 220-225.
105. Mühlemann, K., Matter, H.C., Tauber, M.G., Bodmer, T., 2003. Nationwide surveillance of nasopharyngeal Streptococcus pneumoniae isolates from children with respiratory infection, Switzerland, 1998-1999. J. Infect. Dis. 187, 589-596.
106. Musher, D.M., 1992. Infections caused by Streptococcus pneumoniae: clinical spectrum, pathogenesis, immunity, and treatment. Clin. Infect. Dis. 14, 801-807.
107. Nachman, S., Kim, S., King, J., Abrams, EJ., Margolis, D., Petru, A., Shearer, W., Smith, E., Moye, J., Blanchard, S., Hawkins, E., Bouquin, P., Vink, P., Benson, M., Estep, S., Malinoski, F., 2003. Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants withhuman immunodeficiency virus type 1 infection. Pediatrics 112, 66-73.
108. Nayak, A.R., Tinge, S.A., Tart, R.C., McDaniel, L.S., Briles, D.E., Curtiss III, R., 1998. A live recombinant avirulent oral Salmonella vaccine expressing pneumococcal surface protein A induces protective responses against Streptococcus pneumoniae. Infect. Immun. 66, 3744-3751.
109. Nielsen, S.V., Henrichsen, J., 1996. Incidence of invasive pneumococcal disease and distribution of capsular types of pneumococci in Denmark, 1989-94. Epidemiol. Infect. 117, 411-416.
110. Nieminen, T., Eskola, J., Käyhty, H., 1998. Pneumococcal conjugate vaccination in adults: circulating antibody secreting cell response and humoral antibody responses in saliva and in serum. Vaccine 16, 630-636.
111. Nieminen, T., Käyhty, H., Leroy, O., Eskola, J., 1999. Pneumococcal conjugate vaccination in toddlers: mucosal antibody response measured as circulating antibody-secreting cells and as salivary antibodies. Pediatr. Infect. Dis. J. 18, 764-772.
112. Nurkka, A., Ahman, H., Korkeila, M., Jantti, V., Käyhty, H., Eskola, J., 2001. Serum and salivary anti-capsular antibodies in infants and children immunized with the heptavalent pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J. 20, 25-33.
113. Obaro, S.K., Adegbola, R.A., Banya, W.A., Greenwood, B.M., 1996. Carriage of pneumococci after pneumococcal vaccination. Lancet 348, 271-272.
114. Obaro, S.K., Huo, Z., Banya, W.A., Henderson, D.C., Monteil, M.A., Leach, A., Greenwood, B.M., 1997. A glycoprotein pneumococcal conjugate vaccine primes for antibody responses to a pneumococcal polysaccharide vaccine in Gambian children. Pediatr. Infect. Dis. J. 16, 1135-1140.
115. Obaro, S., Enwere, G., Deloria, M., et al., 2000a. Safety and immunogenicity of a single injection of 9-valent pneumococcal conjugate vaccine mixes with DTP-Hib (Tetramune) in Gambian infants. In: Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Toronto, Canada, Sept. 17-20, 2000. American Society for Microbiology, Washington, DC.
116. Obaro, S.K., Adegbola, R.A., Chang, I., Banya, W.A., Jaffar, S., McAdam, K.W., Greenwood, B.M., 2000b. Safety and immunogenicity of a nonavalent pneumococcal vaccine conjugated to CRM197 administered simultaneously but in a separate syringe with diphtheria, tetanus and pertussis vaccines in Gambian infants. Pediatr. Infect. Dis. J. 19, 463-469.
117. O'Brien, K.L., Steinhoff, M.C., Edwards, K., Keyserling, H., Thorns, M.L., Madore, D., 1996. Immunologic priming of young children by pneumococcal glycoprotein conjugate, but not polysaccharide, vaccines. Pediatr. Infect. Dis. J. 15, 425-430.
118. O'Brien, K.L., Swift, A.J., Winkelstein, J.A., Santosham, M., Stover, B., Luddy, R., Gootenberg, J.E., Nold, J.T., Eskenazi, A., Snader, S.J., Lederman, H.M., 2000. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM(197) among infants with sickle cell disease. Pneumococcal Conjugate Vaccine Study Group. Pediatrics 106, 965-972.
119. O'Brien, K.L., Moulton, L.H., Reid, R., Weatherholtz, R., Oski, J., Brown, L., Kumar, G., Parkinson, A., Hu, D., Hackell, J., Chang, I., Kohberger, R., Siber, G., Santosham, M., 2003. Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial. Lancet 362, 355-361.
120. Pastor, P., Medley, F., Murphy, T.V., 1998. Invasive pneumococcal disease in Dallas County, Texas: results from population-based surveillance in 1995. Clin. Infect. Dis. 26, 590-595.
121. Pelton, S.I., Klein, J.O., 2002. The future of pneumococcal conjugate vaccines for prevention of pneumococcal diseases in infants and children. Pediatrics 110, 805-814.
122. Pichichero, M.E., Shelly, M.A., Treanor, J.J., 1997. Evaluation of a pentavalent conjugated pneumococcal vaccine in toddlers. Pediatr. Infect. Dis. J. 16, 72-74.
123. Powers, D.C., Andersen, E.L., Lottenbach, K., Mink, C.M., 1996. Reactogenicity and immunogenicity of a protein-conjugated pneumococcal oligosaccharide vaccine in older adults. J. Infect. Dis. 173, 1014-1018.
124. Puumalainen, T., Zeta-Capeding, M.R., Käyhty, H., Lucero, M.G., Auranen, K., Leroy, O., Nohynek, H., 2002. Antibody response to an eleven valent diphtheria- and tetanus-conjugated pneumococcal conjugate vaccine in Filipino infants. Pediatr. Infect. Dis. J. 21, 309-314.
125. Reinert, R.R., Hoban, D.J., Felmingham, D., Pluim, J., 2001a. Worldwide surveillance of antimicrobial resistance among clinical isolates of Streptococcus pneumoniae and Streptococcus pyogenes: results from PROJEKT (1999-2000). In: Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2001. American Society for Microbiology, Washington, DC.
126. Reinert, R.R., Simic, S., Al-Lahham, A., Reinert, S., Lemperle, M., Lütticken, R., 2001b. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients with respiratory tract infections in Germany from 1998 to 1999: results of a national surveillance study. J. Clin. Microbiol. 39, 1187-1189.
127. Reinert, R.R., Al-Lahham, A., Lemperle, M., Tenholte, C., Briefs, C., Haupts, S., Gerards, H.H., Lutticken, R., 2002a. Emergence of macrolide and penicillin resistance among invasive pneumococcal isolates in Germany. J. Antimicrob. Chemother. 49, 61-68.
128. Reinert, R.R., Appelbaum, P.C., and the PneumoWorld Study Group., 2002b. Surveillance of antibiotic resistance among clinical isolates of Streptococcus pneumoniae in 2000/2001 in Europe - first results of the PneumoWorld Study. In: Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 27-30, 2002, San Diego, CA, USA. Abstract C2-1623, p. 102.
129. Reinert, R.R., Lütticken, R., Bryskier, A., Al-Lahham, A., 2003a. Macrolide-resistant Streptococcus pneumoniae and Streptococcus pyogenes in the pediatric population in Germany during 2000-2001. Antimicrob. Agents Chemother. 47, 489-493.
130. Reinert, R.R., Muckel, S., Al-Lahham, A., Spratt, E.G., Brueggemann, A.B., Hakenbeck, R., Lütticken, R., 2003b. Characterization of German penicillin non-susceptible serotype 23F pneumococci using multilocus sequence typing. J. Med. Microbiol. 52, 981-987.
131. Rennels, M.B., Edwards, K.M., Keyserling, H.L., Reisinger, K.S., Hogerman, D.A., Madore, D.V., Chang, I., Paradiso, P.R., Malinoski, F.J., Kimura, A., 1998. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics 101, 604-611.
132. Robbins, J.B., Lee, C.J., Rastogi, S.C., Schiffman, G., Henrichsen, J., 1979. Comparative immunogenicity of group 6 pneumococcal type 6A(6) and type 6B(26) capsular polysaccharides. Infect. Immun. 26, 1116-1122.
133. Saeland, E., Jakobsen, H., Ingolfsdottir, G., Sigurdardottir, S.T., Jonsdottir, I., 2001. Serum samples from infants vaccinated with a pneumococcal conjugate vaccine, PncT, protect mice against invasive infection caused by Streptococcus pneumoniae serotypes 6A and 6B. J. Infect. Dis. 183, 253-260.
134. Sarnaik, S., Kaplan, J., Schiffman, G., Bryla, D., Robbins, J.B., Schneerson, R., 1990. Studies on pneumococcus vaccine alone or mixed with DTP and on pneumococcus type 6B and Haemophilus influenzae type b capsular polysaccharide-tetanus toxoid conjugates in two- to five-year-old children with sickle cell anemia. Pediatr. Infect. Dis. J. 9, 181-186.
135. Schmitt, H.J., Faber, J., Lorenz, L, Schmöle-Thoma, B., Ahlers, N., 2003. The safety, reactogenicity and immunogenicity of a 7-valent pneumococcal conjugate vaccine (7VPnC) concurrently administered with a combination DTaP-IPV-Hib vaccine. Vaccine 21, 3653-3662.
136. Schneerson, R., Robbins, J.B., Parke Jr., J.C., Bell, C., Schlesselman, J.J., Sutton, A., Wang, Z., Schiffman, G., Karpas, A., Shiloach, J., 1986. Quantitative and qualitative analyses of serum antibodies elicited in adults by Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-tetanus toxoid conjugates. Infect. Immun. 52, 519-528.
137. Schuchat, A., Flannery, B., Heffernan, R., Hadler, J., Harrison, L., Reingold, K., Gallagher, K., Whitney, C.G., 2004. Invasive pneumococcal disease in HIV-AIDS: Has introduction of 7-valent pneumococcal conjugate vaccine (PCV-7) reduced HIV-related disease burden in the US? In: Programme and Abstracts of the 4th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD-4), May 9-13, 2004, Helsinki, Finland. Abstract EPI-05.
138. Semczuk, K., Dzierzanowska-Fangrat, K., Lopaciuk, U., Gabinska, E., Jozwiak, P., Dzierzanowska, D., 2004. Antimicrobial resistance of Streptococcus pneumoniae and Haemophilus influenzae isolated from children with community-acquired respiratory tract infections in Central Poland. Int. J. Antimicrob. Agents 23, 39-43.
139. Setchanova, L., 1995. Clinical isolates and nasopharyngeal carriage of antibiotic-resistant Streptococcus pneumoniae in Hospital for Infectious Diseases, Sofia, Bulgaria 1991-1993. Microb. Drug Resist. 1, 79-84.
140. Setchanova, L., Tomasz, A., 1999. Molecular characterization of penicillin-resistant Streptococcus pneumoniae isolates from Bulgaria. J. Clin. Microbiol. 37, 638-648.
141. Shelly, M.A., Jacoby, H., Riley, G.J., Graves, B.T., Pichichero, M., Treanor, J.J., 1997. Comparison of pneumococcal polysaccharide and CRM197-conjugated pneumococcal oligosaccharide vaccines in young and elderly adults. Infect. Immun. 65, 242-247.
142. Shinefield, H.R., Black, S., 2000. Efficacy of pneumococcal conjugate vaccines in large scale field trials. Pediatr. Infect. Dis. J. 19, 394-397.
143. Shinefield, H.R., Black, S., Ray, P., Chang, I., Lewis, N., Fireman, B., Hackell, J., Paradiso, P.R., Siber, G., Kohberger, R., Madore, D.V., Malinowski, F.J., Kimura, A., Le, C., Landaw, I., Aguilar, J., Hansen, J., 1999. Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers. Pediatr. Infect. Dis. J. 18, 757-763.
144. Shinefield, H., Black, S., Ray, P., Fireman, B., Schwalbe, J., Lewis, E., 2002. Efficacy, immunogenicity and safety of heptavalent pneumococcal conjugate vaccine in low birth weight and preterm infants. Pediatr. Infect. Dis. J. 21, 182-186.
145. Siber, G., 2002. WHO meeting: definition and evaluation of immune correlates of protection against pneumococcal infection in children that can serve as the basis for licensure of future pneumococcal conjugate vaccines. In: Abstracts of the 3rd International Symposium on Pneumococci and Pneumococcal Diseases, Anchorage, May 5-8, 2002.
146. Sigurdardottir, S.T., Vidarsson, G., Gudnason, T., Kjartansson, S., Kristinsson, K.G., Jonsson, S., Valdimarsson, H., Schiffman, G., Schneerson, R., Jonsdottir, I., 1997. Immune responses of infants vaccinated with serotype 6B pneumococcal polysaccharide conjugated with tetanus toxoid. Pediatr. Infect. Dis. J. 16, 667-674.
147. Sigurdardottir, S., Gudnason, I., Kristinsson, K., et al., 2000. Safety and immunogenicity of two different formulations of 11-valent pneumococcal polysaccharide conjugate vaccines in healthy Icelandic infants. In: Abstracts of the 2nd International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD), Sun City, South Africa, 2000.
148. Simell, B., Kilpi, T.M., Kayhty, H., 2002. Pneumococcal carriage and otitis media induce salivary antibodies to pneumococcal capsular polysaccharides in children. J. Infect. Dis. 186, 1106-1114.
149. Skoczynska, A., Hryniewicz, W., 2003. Genetic relatedness, antibiotic susceptibility, and serotype distribution of Streptococcus pneumonias responsible for meningitis in Poland, 1997-2001. Microb. Drug Resist. 9, 175-182.
150. Spanjaard, L., van der Ende, A., Rumke, H., Dankert, J., van Alphen, L., 2000. Epidemiology of meningitis and bacteraemia due to Streptococcus pneumoniae in The Netherlands. Acta Paediatr. 89, 22-26.
151. Steinhoff, M.C., Edwards, K., Keyserling, H., Thoms, M.L., Johnson, C., Madore, D., Hogerman, D., 1994. A randomized comparison of three bivalent Streptococcus pneumoniae glycoprotein conjugate vaccines in young children: effect of polysaccharide size and linkage characteristics. Pediatr. Infect. Dis. J. 13, 368-372.
152. Storek, J., Mendelman, P.M., Witherspoon, R.P., McGregor, B.A., Storb, R., 1997. IgG response to pneumococcal polysaccharide-protein conjugate appears similar to IgG response to polysaccharide in bone marrow transplant recipients and healthy adults. Clin. Infect. Dis. 25, 1253-1255.
153. Syriopoulou, V., Daikos, G.L., Soulis, K., Michos, A., Alexandrou, H., Pavlopoulou, I., Pagali, I.P.A., Hadjichristodoulou, C., Theodoridou, M., 2000. Epidemiology of invasive childhood pneumococcal infections in Greece. Acta Paediatr. 89, 30-34.
154. Trupl, J., Hupkova, H., Jacobs, M.R., 1997. The incidence of penicillin-resistant pneumococci in the Slovak Republic. Chemotherapy 43, 316-322.
155. Urbaskova, P., Trupl, J., Hupkova, H., Appelbaum, P.C., Jacobs, M.R., 1996. In vitro susceptibility of pneumococci to trovafloxacin, penicillin G, and other antimicrobial agents in the Czech Republic and Slovakia. Eur. J. Clin. Microbiol. Infect. Dis. 15, 686-688.
156. Väkeväinen, M., Eklund, C., Eskola, J., Käyhty, H., 2001. Cross-reactivity of antibodies to type 6B and 6A polysaccharides of Streptococcus pneumoniae, evoked by pneumococcal conjugate vaccines, in infants. J. Infect. Dis. 184, 789-793.
157. Veenhoven, R., Bogaert, D., Uiterwaal, C., Brouwer, C., Kiezebrink, H., Bruin, J., Ijzerman, E., Hermans, P., de Groot, R., Zegers, B., Kuis, W., Rijkers, G., Schilder, A., Sanders, E., 2003. Effect of conjugate pneumococcal vaccine followed by polysaccharide pneumococcal vaccine on recurrent acute otitis media: a randomised study. Lancet 361, 2189-2195.
158. Vergision, A., Malfroot, D., Tuerlinckx, D., Verhaegen, J., Slachmuylders, J., 2003. The Belgian IPD survey, a one-year prospective survey of invasive pneumococcal disease in children under 5 years. Abstract of the 13th European Congress of Clinical Microbiology and Infectious Diseases, Glasgow, UK, 10-13 May 2003. Abstract P1627. Clin. Microbiol. Infect. 9, 399.
159. Vernacchio, L., Neufeld, E.J., MacDonald, K., Kurth, S., Murakami, S., Hohne, C., King, M., Molrine, D., 1998. Combined schedule of 7-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal vaccine in children and young adults with sickle cell disease. J. Pediatr. 133, 275-278.
160. Vidarsson, G., Sigurdardottir, S.T., Gudnason, T., Kjartansson, S., Kristinsson, K.G., Ingolfsdottir, G., Jonsson, S., Valdimarsson, H., Schiffman, G., Schneerson, R., Jonsdottir, I., 1998. Isotypes and opsonophagocytosis of pneumococcus type 6B antibodies elicited in infants and adults by an experimental pneumococcus type 6B- tetanus toxoid vaccine. Infect. Immun. 66, 2866-2870.
161. von Kries, R., Siedler, A., Schmitt, H.J., Reinert, R.R., 2000. Proportion of invasive pneumococcal infections in German children preventable by pneumococcal conjugate vaccines. Clin. Infect. Dis. 31, 482-487.
162. von Kries, R., Hermann, M., Al-Lahham, A., Siedler, A., Reinert, R.R., 2002a. Will the 7-valent pneumococcal vaccine have a similar impact on all invasive pneumococcal infections in children in Germany as in the Kaiser Permanente Trial?. Eur. J. Pediatr. 161, S140-S143.
163. von Kries, R., Hermann, M., Hachmeister, A., Siedler, A., Schmitt, H.J., Al-Lahham, A., Reinert, R.R., 2002b. Prediction of the potential benefit of different pneumococcal conjugate vaccines on invasive pneumococcal disease in German children. Pediatr. Infect. Dis. J. 21, 1017-1023.
164. Whitney, C., 2004. Effect of pneumococcal conjugate vaccine on invasive disease in the US In: Programme and Abstracts of 4th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD-4), May 9-13, 2004, Helsinki, Finland. Abstract PSV1-02.
165. Whitney, C.G., Farley, M.M., Hadler, J., Harrison, L.H., Bennett, N.M., Lynfield, R., Reingold, A., Cieslak, P.R., Pilishvili, T., Jackson, D., Facklam, R.R., Jorgensen, J.H., Schuchat, A., 2003. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N. Engl. J. Med. 348, 1737-1746.
166. WHO, 1999. Pneumococcal vaccines. WHO Position Paper. Wkly Epidemiol. Rec., vol. 74, pp. 177-183.
167. Wong, W.Y., Overturf, G.D., Powars, D.R., 1992. Infection caused by Streptococcus pneumoniae in children with sickle cell disease: epidemiology, immunologic mechanisms, prophylaxis, and vaccination. Clin. Infect. Dis. 14, 1124-1136.
168. Wuorimaa, T., Käyhty, H., 2002. Current state of pneumococcal vaccines. Scand. J. Immunol. 56, 111-129.
169. Wuorimaa, T., Dagan, R., Eskola, J., Janco, J., Ahman, H., Leroy, O., Käyhty, H., 2001a. Tolerability and immunogenicity of an eleven-valent pneumococcal conjugate vaccine in healthy toddlers. Pediatr. Infect. Dis. J. 20, 272-277.
170. Wuorimaa, T., Dagan, R., Vakevainen, M., Bailleux, F., Haikala, R., Yaich, M., Eskola, J., Käyhty, H., 2001b. Avidity and subclasses of IgG after immunization of infants with an 11-valent pneumococcal conjugate vaccine with or without aluminum adjuvant. J. Infect. Dis. 184, 1211-1215.
171. Wuorimaa, T., Käyhty, H., Leroy, O., Eskola, J., 2001c. Tolerability and immunogenicity of an 11-valent pneumococcal conjugate vaccine in adults. Vaccine 19, 1863-1869.
172. Yu, X., Gray, B., Chang, S., Ward, J.I., Edwards, K.M., Nahm, M.H., 1999. Immunity to cross-reactive serotypes induced by pneumococcal conjugate vaccines in infants. J. Infect. Dis. 180, 1569-1576.
173. Zarkowsky, H.S., Gallagher, D., Gill, P.M., Wang, W.C., Falletta, J.M., Lande, W.M., Levy, P.S., Verter, J.I., Wethers, D., 1986. Bacteremia in sickle hemoglobinopathies. J. Pediatr. 109, 579-585.
174. Zielen, S., Buhring, L, Strnad, N., Reichenbach, J., Hofmann, D., 2000. Immunogenicity and tolerance of a 7-valent pneumococcal conjugate vaccine in nonresponders to the 23-valent pneumococcal vaccine. Infect. Immun. 68, 1435-1440.